Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim in Active Crohn's Disease
NCT00206674Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2004
- Primary completion
- Jun 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Sargramostim with Placebo (2 arms). Primary endpoint: Induction of clinical response and/or remission as defined by decrease in CDAI score at 8 weeks. Started Sep 2004; status: completed.
02
Drugs
sargramostim
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00206674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206674.